TICKERNOMICS Sign up
Last Update: 2024-03-28 02:14:27
Werewolf Therapeutics Inc. ( HOWL ) https://werewolftx.com
6.04USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
HOWL
141.60%
SPY
32.74%
HOWL
0.00%
SPY
92.93%
HOWL
0.00%
SPY
224.41%
HOWL
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
236.21
134.52
0.12
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-6.68
9.18
2.12
-39.99
0.00
-3.84
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-156.88
100.00
-144.07
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
-21.85
-25.37
0.00
Other Earnings and Cash Flow Stats:
Werewolf Therapeutics Inc. ( HOWL ) Net Income TTM ($MM) is -41.63
Werewolf Therapeutics Inc. ( HOWL ) Operating Income TTM ($MM) is -47.19
Werewolf Therapeutics Inc. ( HOWL ) Owners' Earnings Annual ($MM) is 0.00
Werewolf Therapeutics Inc. ( HOWL ) Current Price to Owners' Earnings ratio is 0.00
Werewolf Therapeutics Inc. ( HOWL ) EBITDA TTM ($MM) is -45.50
Werewolf Therapeutics Inc. ( HOWL ) EBITDA Margin is -144.07%
Capital Allocation:
Werewolf Therapeutics Inc. ( HOWL ) has paid 0.00 dividends per share and bought back -10.243048 million shares in the past 12 months
Werewolf Therapeutics Inc. ( HOWL ) has increased its debt by 17.972 million USD in the last 12 months
Capital Structure:
Werewolf Therapeutics Inc. ( HOWL ) Interest-bearing Debt ($MM) as of last quarter is 32
Werewolf Therapeutics Inc. ( HOWL ) Annual Working Capital Investments ($MM) are 3
Werewolf Therapeutics Inc. ( HOWL ) Book Value ($MM) as of last quarter is 111
Werewolf Therapeutics Inc. ( HOWL ) Debt/Capital as of last quarter is 29%
Other Balance Sheet Stats:
Werewolf Therapeutics Inc. ( HOWL ) has 134 million in cash on hand as of last quarter
Werewolf Therapeutics Inc. ( HOWL ) has 19 million of liabilities due within 12 months, and long term debt 39 as of last quarter
Werewolf Therapeutics Inc. ( HOWL ) has 39 common shares outstanding as of last quarter
Werewolf Therapeutics Inc. ( HOWL ) has 0 million USD of preferred stock value
Academic Scores:
Werewolf Therapeutics Inc. ( HOWL ) Altman Z-Score is -0.26 as of last quarter
Werewolf Therapeutics Inc. ( HOWL ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Werewolf Therapeutics Inc. ( HOWL ) largest shareholder is owning shares at 0.00 ($MM) value
Ra Capital Management, L.P.(an insider) Bought 1853000 shares of Werewolf Therapeutics Inc. ( HOWL ) for the amount of $4095130.00 on 2023-01-06
8.11% of Werewolf Therapeutics Inc. ( HOWL ) is held by insiders, and 78.20% is held by institutions
Werewolf Therapeutics Inc. ( HOWL ) went public on 2021-04-30
Other Werewolf Therapeutics Inc. ( HOWL ) financial metrics:
FCF:-41.33
Unlevered Free Cash Flow:-27.25
EPS:-0.85
Operating Margin:-156.88
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-29.76
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Werewolf Therapeutics Inc. ( HOWL ) :
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.